Alzheimer's disease (AD), the most common dementing disorder of late life, is a major cause of disability and death in the elderly. AD is characterized and diagnosed by distinctive neuropathological alterations including extracellular deposits of the ?-amyloid (A?) peptide. Epidemiological investigations have demonstrated that AD is a complex, age-related disorder with numerous proposed genetic and environmental etiologies. Human genetic studies have shown that altered dosage and mutations in the amyloid precursor protein gene as well as mutations in presenilin 1 and presenilin 2 genes all cause early-onset AD, while the APOE gene is major risk factor in late-onset AD. Considerable evidence suggests that these genetic factors alter A? metabolism and/or A? deposition. However, the AD genes identified thus far account for less than 30% of genetic risk for AD. Due to the inherent variability and genetic heterogeneity in late-onset neurodegenerative disorders, the identification of the remainder of the genetic and environmental factors that modulate AD risk have proven extremely difficult. Over the past decade and a half, several groups, including our own, have focused on the development of accurate and defined mouse models of AD, in which both the genetic background and environmental exposure can be precisely and reproducibly modified in an effort to gain insight into factors that modify APP processing, the production and deposition of A? peptides, the onset of dementia and the neuropathological abnormalities that occur in AD. In the previous funding period of this grant application, we generated congenic strains, in which a human AD transgene was transferred into different inbred mouse strains. We subsequently characterized the effects of different inbred genetic backgrounds and specific genetic alterations on A? metabolism and deposition and other AD phenotypes and identified unique mouse genetic loci that regulate metabolism and deposition. In addition, in preliminary studies we determined that the effects of an environmental factor, namely high-fat/high-cholesterol diets, on brain A? levels are dependent upon the genetic background of the mice. The current studies seek to expand and extend these studies with a focus on genetic and environmental factors that regulate A? metabolism and deposition in two inbred mouse strains with the most divergent A? phenotypes, C57BL/6J and A/J, using the unique genetic resources available for these strains.
The specific aims of the current proposal are to: 1) Identify mouse chromosomes with gene(s) that regulate A? metabolism and deposition. 2) Identify and characterize genetic loci that regulate A? deposition. 3) Characterize genetic loci responsible for diet-induced alterations in A? metabolism and deposition.
Human genetic studies have demonstrated that accumulation and aggregation of small peptide fragments, termed beta-amyloid, is central to the disease mechanisms underlying Alzheimer's disease, a major cause of death and disability in the elderly. However, it remains unclear how the multitude of postulated genetic and environmental risk factors for human AD directly influence the production and aggregation of beta-amyloid. The current studies seek to identify and characterize additional genetic and environmental (namely high-fat/high-cholesterol diets) factors influence beta-amyloid generation and deposition within the brains of transgenic mouse models of AD.
|Bhaskar, Kiran; Maphis, Nicole; Xu, Guixiang et al. (2014) Microglial derived tumor necrosis factor-* drives Alzheimer's disease-related neuronal cell cycle events. Neurobiol Dis 62:273-85|
|Lee, Sungho; Xu, Guixiang; Jay, Taylor R et al. (2014) Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J Neurosci 34:12538-46|
|Wilkinson, Brandy L; Cramer, Paige E; Varvel, Nicholas H et al. (2012) Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging 33:197.e21-32|
|Lee, Sungho; Varvel, Nicholas H; Konerth, Megan E et al. (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 177:2549-62|
|Bhaskar, Kiran; Konerth, Megan; Kokiko-Cochran, Olga N et al. (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19-31|
|Varvel, Nicholas H; Bhaskar, Kiran; Kounnas, Maria Z et al. (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119:3692-702|
|Muresan, Virgil; Varvel, Nicholas H; Lamb, Bruce T et al. (2009) The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J Neurosci 29:3565-78|
|Hock, Brian J; Lattal, K Matthew; Kulnane, Laura Shapiro et al. (2009) Pathology associated memory deficits in Swedish mutant genome-based amyloid precursor protein transgenic mice. Curr Aging Sci 2:205-13|
|Varvel, Nicholas H; Bhaskar, Kiran; Patil, Anita R et al. (2008) Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci 28:10786-93|
|Ryman, Davis; Gao, Yuan; Lamb, Bruce T (2008) Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease. Neurobiol Aging 29:1190-8|
Showing the most recent 10 out of 14 publications